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Abstract
Effects of Type -I Collagen Fractional Composition and Pyridinium Crosslink
Content on Cortical Bone Strength in the Human Femur.
Michael Blair Rice

Type-I collagen's role in the formation of bone and its inherent strength have been
well documented by studies in genetic diseases such as Osteogenesis Imperfecta. Type-I
collagen's role in healthy bone, and the changes that occur to collagen during aging,
which may eventually lead to osteoporosis, is less understood. Changes that may occur
include differences in collagen production and in its processing such as differences in
glycosylation and the hydroxylation of specific amino acid residues. Changes in the
reducible and non-reducible crosslink content, or changes in the ratio of crosslinks to
total collagen may also occur. The present study investigated 1) type-I collagen content
in cortical bone from the human femur, 2) the mature, non-reducible pyridinium crosslink
content of this bone, and 3) assessed the potential relationships of these findings to
fracture resistance and to the age and sex of the bone donor. It was hypothesized that
higher amounts of type-I collagen and pyridinium crosslinks per dry weight of bone
would correspond to increased force required for fracture.
The results indicate that the percentage of type-I collagen correlates to tension
fracture resistance. Collagen content also appears to decrease with increasing age of the
donor, although these data did not reach significance. A gender-based difference in
collagen content of cortical bone was also observed. Pyridinium content did not correlate
with either tension or shear fracture resistance in females, but a significant relationship
was observed in male samples. Pyridinium content did not show a significant
relationship to either age or sex, although the data suggest a larger sample size may
reveal that pyridinium amount does decrease in females as they age. The ratio of
pyridinium to collagen showed no relationship to fracture resistance or to age, but a
gender-based difference was observed.
These studies suggest that type-I collagen content of bone is directly related to
tension fracture resistance. Type-I collagen amount may also decrease during aging, and
there are significant differences in the fractional composition of collagen in bone between
males and females. The pyridinium content does not effect the fracture resistance except
in the male sub-group; this may relate to a lower ratio of pyridinium to collagen in male
cortical bone. The pyridinium amount may decrease in females as they age, although, to
date only a trend toward significance could be demonstrated.
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Introduction

Osteoporosis is a disease characterized as having a low bone density and a
deterioration of the microstructure of bone, leading to a decrease in bone strength and an
increase in fracture risk (1-6). Factors that influence bone strength are split into two
categories: material properties, and geometric properties (2,3,7-11). Material properties
include collagen content, hydroxyapatite content, type and amount of non-collagenous
proteins, and maturation of bone (1,3). Geometric properties include bone mineral density,
organization of collagen fibrils, osteon size and number, distribution of mass about the
bone, and trabecular connectivity (1-4,12,13).
It is generally accepted that there are two classifications of osteoporosis, referred
to as Primary and Secondary Osteoporosis (3,14). Primary Osteoporosis is a condition of
bone fragility found in some post-menopausal women and in some men and women as a
consequence of age (3). Primary osteoporosis is further divided into two types (14,15).
Type-1 is believed to be a consequence of the decrease of circulating estrogen seen in
post-menopausal women, that allows an increased rate of osteoclast activity to degrade
bone faster than it is replaced (2,3,7,16-22). Type-2 refers to osteoporosis involving older
men and women that appears to be caused by a variety of events associated with aging,
with fracture incidence exacerbated by an increased propensity to fall (3,14,23). Secondary
osteoporosis refers to bone loss and skeletal fragility due to disease in which the strength
of bone has been compromised (3).
Fractures of the hip/femoral neck, vertebrae, and of the distal forearm (termed
Colle's fracture) account for almost 75% of all osteoporotic fractures (6,14,24,25). Although
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the menopause is a primary risk factor for osteoporosis, there are additional risk factors
including race, sex, and genetic predisposition, and environmental factors such as diet,
attainment of peak bone mass, physical activity, and smoking (3,11,14,15,19). It is estimated
that roughly 40% of females of European descent over the age of fifty will eventually
sustain some type of osteoporotic fracture (1,6). Men over fifty and of European descent
face a lifetime fracture risk of about 13% (1,6). In 1991 an estimated 7 to 10 billion dollars
was spent on care for patients due to osteoporosis in the United States (14). With the
increasing age of the population, this amount is sure to continue to rise.
Bone is a living tissue that protects the body’s internal organs, provides sites of
muscle attachment for locomotion, and serves physiological functions such as
maintaining calcium and phosphate homeostasis in the body and providing a site for
production of hematopoeitic tissues (3,15,16,21,26-28). Bone is continuously remodeled
throughout life; osteoclasts resorb bone while osteoblasts form new bone (3,11,14-16,19-22,26).
This is a tightly coupled process that is essential in maintaining bone's physical and
physiological functionalities (3,19,21,29,30). Preosteoclasts are recruited to bone where they
recognize proteins on the bone’s surface. In a process not well understood, the
preosteoclasts differentiate into osteoclast cells that respond to local, as well as systemic,
signaling. The osteoclasts degrade old, damaged bone that is to be replaced by new bone.
During degradation, signal molecules that became trapped in the bone are released and
aid in the recruitment of preosteoblasts to the site. These cells then differentiate into
osteoblasts to produce the new bone. As the body ages, resorption outpaces formation,
the coupled interaction is no longer balanced, and bone is lost (3,14,20,26). The menopause
is believed to be the principle risk factor for type-I primary osteoporosis, since circulating
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estrogen, which is believed to suppress the osteoclast's activity, is no longer found at
adequate levels (3,7,16,18,22). Once this occurs, osteoclastic resorption of bone can further
outpace osteoblastic formation of bone, which leads to a decrease in bone mass and
consequently bone strength.
Osteoclasts are large multinucleated cells that are formed following the fusion of
mononuclear pre-osteoclasts. In cortical bone the osteoclasts attach to the endosteal and
periosteal surfaces of bone, especially in areas of bone that have been damaged. A site
actively being degraded may have only one or two osteoclasts attached to the resorption
site (20,27).

A series of invaginations of the plasma membrane are formed where the

osteoclast attaches to bone. These invaginations define the ruffled border, enclosing
areas of the bone surface by the osteoclast's plasma membrane. The osteoclasts become
polarized, with golgi apparati and lysozomes found between the nucleus and the ruffled
border (18,20,21). Lysozomal enzymes and hydrogen ions are secreted into the space
between the bone and the osteoclast, causing the calcium crystals of bone to be dissolved
and exposing the collagenous matrix. This is then degraded by collagenase and
(possibly) cathepsins secreted by the osteoclast (18-21,27). The formation of new bone in
adults only happens where the degradation of old bone has occurred; these are called
remodeling sites

(21)

(Figure 1).

Bone is made up of an organic meshwork of proteins and an inorganic "cement"
made primarily of hydroxyapatite calcium crystals. Both components are produced by the
osteoblast. Of bone, 35% of its mass is the organic matrix. About 90% of this organic
matrix is comprised of type-I collagen fibers, while the other 10% represents other
collagen types and various non-collagenous proteins (NCP's) (10,15,26,27,29-32). The

4

Figure 1
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Figure 1. 1. Preosteoclasts are recruited to damaged bone where they fuse into
multinucleated osteoclasts. 2. The osteoclasts form a ruffled border, effectively sealing an
area of bone for degradation. 3. Osteoclasts acidify the sealed zone dissolving the
hydroxyapatite, and release collagenase and other enzymes to destroy the protein matrix
forming a resorption pit. 4. Preosteoblasts are recruited to the site possibly by signal
molecules released during degradation. 5. Osteoblasts produce type-I collagen and noncollagenase proteins which form a new matrix, termed the osteoid. 6. The osteoid matures
and becomes mineralized forming new bone, while the osteoblasts continue to produce more
protein to be mineralized.
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meshwork of proteins gives bone tensile strength, allowing it to withstand the pulling
forces that continuously act on bone (5,10,28). The type-I collagen fibers are arranged in
such a way as to produce a scaffold which becomes calcified. Mineral deposits account
for about 65% of bone mass, mainly in the form of hydroxyapatite crystals
(Ca10(PO4)6(OH)2) (30). These crystals form parallel to the orientation of the meshwork of
proteins, filling the available space and often embedding themselves into the collagen
fibers. The calcium crystals give bone the strength to withstand the compression forces
that are exerted on bone (5,10,28). Throughout this hardened matrix, osteoblasts routinely
become trapped and develop into osteocytes. Surrounding these osteocytes are fluid filled
spaces known as lacunae. The osteocytes extend cellular projections that connect to other
osteocytes and to osteoblasts on the surface of the bone; these projections are surrounded
by fluid filled channels called canaliculae. The osteocytes may aid in maintaining mineral
homeostasis or act as mechano-sensitive cells (21,30). The network of lacunae and
canaliculi is extensive, with an estimated surface area of 1000-5000 mm2 in an adult
human skeleton. Approximately 1.0 - 1.5 liters of bone extracellular fluid (ECF) fill these
periosteocytic spaces (27).
Collagen is the major constituent of the organic matrix in bone, and accounts for
over 90% of the protein content. Several isotypes of collagens are found in bone,
including types I, III, V and X (24,33). Type-V collagen is found in the pericellular areas
around the osteocytes, and in the canaliculi that surrounds the osteocyte's cellular
projections, but it is not found in the scaffolding of the bone's extracellular matrix (24). In
hyaline cartilage produced by chondrocytes that becomes mineralized, collagen type-X
has been found to be produced immediately before calcification (33). Of all the collagen
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types, type-I collagen is the predominant form found in bone. Synthesis of the type-I
procollagen sub-unit occurs in the osteoblast, where the protein goes through several cotranslational and post-translational modifications before folding into its tertiary structure,
the triple helix. After the procollagen molecule is extruded from the cell and is cleaved
of its terminal extensions, the individual triple helical collagen molecules go through a
structured assembly into five-stranded units that form microfibrils. These microfibrils
assemble into fibrils, which subsequently become organized as collagen fibers. These
collagen fibers are arranged either into orientated layers on the bone, called lamella, or as
loose bundles as is seen in woven bone.
Prior to the mineralization of the newly formed collagen matrix of the osteoid is a
5 to 10 day period of time during which the matrix matures. There are several theories as
to what occurs during maturation, including the crosslinking of collagen fibers, the
removal of a mineralization inhibitor, or the complex formation between collagenous and
non-collagenous proteins. Following the maturation of the osteoid, hydroxyapatite crystal
seeds are deposited, which grow to produce the new mineralized bone (27,30,34).
The type-I procollagen molecule is made up of three sub-units, two alpha-1 subunits (α1(I)) and one alpha-2 sub-unit (α2(I)), together assembling into the triple helix.
The genes for the α1(I) sub-unit and the α2(I) sub-unit are found on chromosomes 17
and 7, respectively (31,36,37). Of the fiber-forming collagens, all have similar genetic
sequences within the exons that code for the amino acids of the triple helix-forming
region of the proteins (33). An ancestral 54 base pair exon appears to have duplicated
itself several times within the genes, as exons of 54 or 108 base pairs, are remarkably
conserved throughout various species, and make up the lengthy triple helix region of the
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proteins (26,36,37). The conservation of the sequence of the 18 amino acid repeats specified
by the 54 base pair repeats is critical to the structure of type-I collagen, and even a single
point mutation within the repeat can have severe to lethal consequences

(33,36-42,47).

Defining the helical domain of the procollagen's sub-units is the amino acid repeat of
glycine-X-Y, where X is usually a proline (Pro), and Y is often hydroxyproline (Hyp)
(26,36,37,41).

Thirty-three percent of type-I collagen's amino acids are glycine while another

15-30% begins as proline; the repeat of Gly-Pro-Hyp represents about 10% of each of the
protein sub-unit's sequence (33,36,43,44).
Translation of collagen's mRNA occurs on the rough endoplasmic reticulum
(32,33,36).

Both of the procollagen chains α1(I) and α2(I) are roughly 160,000 Daltons in

size. Both of the procollagen sub-units consist of a central helical domain (100,000 Da),
a non-helical propeptide extension on the amino end (25,000 Da) that includes a leader
sequence, and a non-helical propeptide extension on the carboxy end (35,000 Da) that
contain cysteine residues for disulfide bonds that help control the folding of the collagen
sub-units into their triple helix form (26,31,33). The leader sequence is a short stretch of
predominately hydrophobic amino acids that are recognized by a signal recognition
particle (SRP) located on the surface of the rough ER. The SRP acts as a receptor and
guides the protein being formed into the membranous rER where co-translational and
post-translational processing occur (43).
During, and immediately after, translation of the procollagen sub-units, several
enzymatic modifications of the protein occur. While translation is occurring, specific
newly incorporated proline and lysine residues are recognized as hydroxylation
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Figure 2. The three modified amino acids that are found in type-I
collagen. Both proline and hydroxyproline residues help form, and
strengthen the triple helix while lysine and hydroxylysine residues may
become glycosylated or form crosslinks between collagen monomers.
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candidates (26,36) (Figure 2). If the amino acid at the Y position is lysine, it can be
hydroxylated to form 5-hydroxylysine and if the amino acid is proline, it can be
hydroxylated to form 4-hydroxyproline. A few proline residues at the X position are
hydroxylated forming 3-hydroxyproline, but this occurs only if the Y proline has been
hydroxylated previously (36). Hydroxyproline (Hyp) is found in abundance in all collagen
types and has a ratio of 0.14 µg Hyp/1.0 µg of type-I collagen (45). The hydroxylation of
prolines and lysines are catalyzed by several types of prolyl- and lysyl-hydroxylases,
respectively (33,43,46). These hydroxylations are completed prior to triple helix formation
and are required for the sub-units to fold into the triple helix; it appears that the formation
of the triple helix may limit the amount of hydroxylation that occurs (38,40,47,48). The
importance of proline and hydroxyproline, which are more correctly identified as imino
acids, is that their chemical structures help form and stabilize the helical structure of
collagen. This occurs in two ways. The imino acids do not allow rotation between the
nitrogen and the α carbon which aids in formation, and the ring structure of the residues
confers rigidity and inflexibility, which limits the bending of the triple helix (41,44) (Figure
3). Hydroxyproline residues also may strengthen the triple helix by forming
intramolecular hydrogen bounds involving water bridges (40,43,44). An example of the
functional importance of these modifications is shown when collagen is formed in the
absence of an active prolyl hydroxylase. These resultant incompletely processed collagen
molecules denature at 24° C, while normal collagen denatures at 39° C (43). The
hydroxylysine residues do not appear to contribute to the stability of the triple helix.
However, hydroxylysine residues contribute to the stability on the collagen fiber as a
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arrows circling the typical N-C bond. These rings also help stabilize the
tertiary structure of the protein, the triple helix, by limiting the amount of
bending of the collagen monomer.
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whole, because hydroxylysine and lysine residues are used to form intramolecular and
intermolecular covalent crosslinks (12,42,43,47,48). After the hydroxylation of certain lysine
residues, carbohydrates become covalently bound to some of the hydroxylysine residues
by galactosyltransferase and glucosyltransferase action (26,33,36,41,49). The carbohydrates
added are the monosaccharide galactose, and galactose-glucose disaccharides (33). The
function of these sugars is not well understood but they may be involved with fibril
assembly outside of the osteoblast, crosslinking of monomers, or the mineralization of the
matrix. Their importance is shown by an increase in the amount of galactosylhydroxylysine in urine (GHYL) that has been reported to correspond to an increase in
fractures (5). Another carbohydrate side chain is found in the C-terminal propeptide,
attached to an asparagine residue. This carbohydrate side chain is composed of Nacetylglucosamine and mannose and may aid in the alignment of the sub-units prior to
formation of the triple helix (26). These covalent modifications occur during translation of
the mRNA, while the protein subunit still remains attached to the ribosome. Removal of
the N-terminal leader sequence precedes release of the polypeptide from the ribosome.
After their release, while still within the ER, the three procollagen sub-units align so that
intrachain and interchain disulfide bonds are formed between cysteine residues found in
the C-terminal propeptide extensions (26,33,38,41,43). The proper alignment of the C-terminal
propeptide extensions, and the amino acid composition of each sub-unit, provides for the
spontaneous formation of the triple helix (26,31,33,38,41). The amino propeptide has
intrachain, but no interchain, disulfide bonds (36). Found in the triple helical region of
each chain is the Gly-X-Y repeat. The triple helix has so little room within its interior
that glycine’s R-group, hydrogen, is the only one small enough to fit inside the triple
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helix (43). Due to this constraint the sub-units of the helix must be staggered so that
glycines' R-groups from each of the sub-units face the interior. This causes the glycine
from one sub-unit to align opposite to the X from another sub-unit, and a hydrogen bond
is formed from the N-H of glycine and the carbonyl oxygen of the X residue (40,43). It has
been proposed that the hydroxyproline residues may form interchain hydrogen bonds.
Intrachain hydrogen bonding involving water bridges and hydroxyproline are believed to
be formed. The number of hydrogen bonds for each Gly-X-Y repeat remains unclear
(33,40).

The way in which the helix is folded also strengthens the fiber as a whole. The
individual sub-units have a left-handed coil with approximately 3.3 residues per turn and
8.7 Å between glycine residues (33,36,43). The sub-units in the collagen triple helix
structure have a rise per residue of 2.9 Å as compared to the 1.5 Å rise per residue for the
alpha helix, a common secondary structure of many proteins (33,43,44). This large rise per
residue probably does not allow for intrachain hydrogen bonds to be formed directly
between residues (as is seen in the alpha helix), but intrachain hydrogen bonds may be
formed involving water bridges (33). The three left-handed helical sub-units form a righthanded tertiary structure, the triple helix (36,40,43,44). The opposing twists of the individual
sub-units and the triple helix insure that collagen can withstand tension without pulling
out the twists (43) (Figure 4).
After the folding of the procollagen sub-units, the soluble procollagen molecule is
transported to the golgi apparatus via microsomal lumen (38). In the golgi, mannose-rich
carbohydrate extensions are added to the molecule, which is then packed into vesicles
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Figure 4
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Figure 4. Collagen's tertiary structure is formed from three left-handed coiled subunits that form a right-handed supercoil, termed the triple helix. On the individual subunits each amino acid residue is 2.9 Å apart with 3.3 residues completing a full turn.
This large rise per residue does not allow intrachain hydrogen bonding to occur except
(possibly) by water bridges. In the interior of the triple helix interchain hydrogen
bonding occurs between glycine's nitrogen-hydrogen and the carbonyl oxygen form
another sub-units "X" residue.

14
for secretion from the cell (32,33). In the vesicles, the resultant tropocollagen molecules
condense laterally into what is called Segment Long Spacing (SLS) crystallites (33,51).
Fibrillogenesis does not occur in the vesicles possibly due to the non-helical propeptide
extensions (31,33). As the vesicles exit the cell, aminopeptidases cleave the aminopropeptide extension, and then carboxypeptidases cleave the C-terminal propeptide
extension (26,33,36,43). Both the amino and the carboxy propeptides are found within the
bone matrix in a phosphorylated form, and may have a function in remodeling, along
with other trapped proteins, upon release by bone degradation (16,21,26,52,53).
Tropocollagen's solubility is immensely decreased once trimmed of the non-helical ends,
and this may aid in the spontaneous fibrillogenesis of the collagen monomers (41) (Figure
5). Once out of the cell and trimmed of its non-helical ends, the molecule is considered a
collagen monomer.
In the extracellular environment the newly trimmed collagen monomers are acted
on by the enzyme lysyl oxidase, an extracellular amine oxidase (33,36,54,55). Lysyl oxidase
converts some of the lysine and hydroxylysine residues into aldehydes by catalyzing the
oxidative deamination of the amino acid’s R-group (33,56,57) (Figure 6). The enzyme
probably uses molecular oxygen as a co-substrate and a hydrogen acceptor (33). The
enzyme is believed to act on collagen monomers or aggregates of microfibrils because
once fiber formation occurs, the enzyme, which is 30,000 Da or multiples thereof, would
not be able to reach into the interior of the fiber (33). Several types of crosslinks are
formed; reducible types include hydroxylysino-5-ketonorleucine (HLKNL), dehydrohydroxylysinonorleucine (DeH-HLNL), and dehydro-histidinohydroxymero desmosine
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Golgi apparatus

“SLS” crystallites

Lysyl Oxidase de-aminates specific
lysine and hydroxylysine residues.

Amino- and Carboxypeptidases cleave the
peptides.

Propeptides are found in the collagenous matrix.

Figure 5. The triple helix passes through the Golgi apparatus where it is further
modified. From the Golgi, the tropocollagen molecules are packed into secretory
vesicles for extrusion from the cell. Inside the vesicles the tropocollagen molecules
form segment long spacing "SLS" crystallites. Upon extrusion from the cell, amino and
carboxy peptidases cleave the propeptides and the resultant collagen molecules are acted
on by lysyl oxidase and can now form the 5-stranded unit.
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Figure 6. Oxidative deamination of hydroxylysine by lysyl oxidase. The resulting
aldehyde can spontaneously react with another hydroxylysine to form a bivalent
crosslink termed Lysinonorleucine. This reacts with another lysine or hydroxylysine to
form the trivalent non-reducible pyridinium crosslinks.
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(HHMD), and the non-reducible pyridinium crosslinks, pyridinoline and
deoxypyridinoline. The DeH-HLNL and the HHMD are lysine-aldehyde derived
crosslinks, and have been detected in early stages of the bone collagen matrix formation.
As the matrix matures and mineralization begins, the hydroxylysine-aldehyde derived
crosslinks, pyridinoline and deoxypyridinoline, predominate (48,57,66). Several studies
have found an increase in lysine hydroxylation in osteoporotic bone, yet do not agree
whether the increase in hydroxylysine is on the α2(I) chain or the α1(I) chain, or both
(5,12,48,58).

The increase in hydroxylysine did not cause a change in pyridinium crosslink

content in osteoporotic bone, but a decrease in HLKNL was noted (48). Also, an increase
in hydroxylysine content in collagen has been correlated to a decrease in trabecular bone
volume.
From the aldehyde derivatives of the hydroxylysine residues, two types of nonreducible trivalent crosslinks are formed, 3-hydroxylysylpyridinoline, formed from three
hydroxylysine residues, and lysylpyridinoline, formed from two hydroxylysines and one
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lysine residue (12,26,33,56,57) (Figure 7). These crosslinks are commonly termed
pyridinolines and deoxypyridinolines, respectively. These non-reducible crosslinks
connect three collagen monomers together and help to stabilize the fibril (26,31,59,62). The
crosslinks are found at two sites in the helical region of the collagen molecule. One
crosslink has residues in the aminotelopeptide regions of two molecules that form a
covalent bond at or near residue 930 in the helical domain of the third monomer. The
second crosslink has residues in the carboxytelopeptide regions of two molecules linked
to residue 87 in the helical domain of the third molecule (42,50) (Figure 8). The telopeptide
regions have been shown to be involved in the proper nucleation and fibril elongation, in
vitro (60). This nucleation and fibril formation may involve crosslinks properly aligning
the collagen monomers. During bone turnover and collagen breakdown, the
pyridinolines are excreted as free and peptide bound crosslinks that can be monitored
along with other markers to predict bone turnover that may indicate fracture risk
(5,15,16,19,26,31,33,53-57,59,61,62).

Pyridinoline appears to be ubiquitous within the body’s

collagen, while the deoxypyridinoline crosslink is found primarily in mineralized tissues,
such as dentin and bone (15,19,55-57,59,62,63). It is estimated that 22% of the crosslinks in
bone are deoxypyridinoline, and the combined concentration of crosslinks is estimated to
be 0.3 moles / 1.0 mole of type-1 collagen (26,57,63,). It is estimated that for every three
type-I collagen monomers there is one pyridinium crosslink. As the crosslinks are being
formed, fibrillogenesis is also occurring. The five-stranded microfibril aggregate appears
to be the next structure formed. This five stranded structure proposed by Smith (64),
satisfies the quarter staggered theory (discussed below), and X-ray microscopy appears to
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Figure 8. Two residues in the helical domain of collagen are known to be
involved in crosslinking. Residue 87 forms a crosslink with residues in the
carboxy propeptide region of two α1(I) sub-units from two other monomers.
Residue 930 forms a crosslink with residues in the amino propeptide regions of
an α1(I) and an α2(I) sub-unit from two other monomers. The ratio of sub-units
involved in crosslinking is believed to be 3.5 : 1.0 in favor of α1(I).
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support this structure (33,43,44,51,64,65). In non-mineralized bone, each monomer is 300 nm
long, and when one is laid down next to another monomer it overlaps it by 3/4 of its
length, leaving about 68 nm non-overlapped at each end. The placement of three more
monomers along side the first two, each at a quarter stagger, forms one unit, with each
monomer 68 nm displaced from the next, and the tail of the first monomer spaced about
40 nm from the head of the fifth. This 40 nm “hole” region, where only four of the five
monomers overlap, is rich in carbohydrates attached to hydroxylysine residues, and these
sugars may play a role in forming this pre-fibril unit, and later during mineralization
(43,44,49).

One aspect under scrutiny questions if charges along the length of the collagen

monomers aid in the staggering of the monomers themselves (33,44). Stacking unit upon
unit forms a single fibril, which along side thousands of other fibrils, forms the tough
collagen fibers. Between fibrils crosslinking also occurs, further strengthening the fiber
(Figure 9).
In the normal production of bone, the orientation of the collagen fibers produced
by the osteoblast is parallel in each layer of collagen, or lamella. Between lamella, the
orientation of the fibers occurs at angles to increase the amount of collagen per volume of
bone (27). The lamellae are laid in sheets on top of each other as seen on the flat surfaces
of bone, such as the periosteum, or deposited in concentric circles, such as around a
Haversian canal or canaliculi (27). Several studies have indicated that collagen fiber
orientation, in response to load bearing, play a significant role in bone strength (10,11).
Instances occur where the fibers are produced rapidly and deposited in unorganized
bundles called woven bone. Woven bone is made at times of fracture healing, bone

Figure 9
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Figure 9. Each collagen monomer is displaced by about one quarter of it's length along
the side of another monomer. Five monomers "quarter-staggered" together form a 5stranded microfibril that when stacked upon each other leave a 40 nm "hole" between the
carboxy end of one monomer and the amino end of the next. This hole regions are rich in
carbohydrates and sites of mineral deposition
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elongation of children, and during specific metabolic diseases (27,52). In fracture healing,
the woven bone is eventually remodeled and mature lamellar bone is deposited. During
bone growth in children, the woven bone allows space for hematopoeitic bone marrow to
form. Soon after the formation of this bone marrow, the woven bone is remodeled and
replaced with mature lamellar bone.
Mineralization of the matrix is also a function of the osteoblast, and occurs only
after matrix maturation. Osteoid maturation and mineralization occurs over a period of
about 5 to 10 days in humans (27,30,66). The maturation of the matrix is not well
understood, fibrils fuse into collagen fibers, non-collagenous proteins interact with the
matrix, while the surrounding microenvironment becomes conducive to mineralization;
however, the signals for mineralization to begin have not yet been identified. The signal
may include the chemical crosslinking of the collagen microfibrils, the removal of a
mineralization inhibitor, or the synthesis and addition of non-collagenous proteins, such
as osteocalcin or osteonectin, to the matrix (12,21,30,34,42,65-69,71). Of the non-collagenous
proteins, osteocalcin and osteonectin are considered probable participants in the
mineralization process. Osteocalcin contains gamma-carboxyglutamic acid residues,
whose two negative charges can bind a calcium ion, though it remains unresolved as to
how much osteocalcin the human bone contains (15,21,26,29,52,68). Also, the bones of
warfarin treated animals, which blocks the γ-carboxylation of glutamic acid in
osteocalcin, appear to be normal in all aspects with the exception of decreased levels of
osteocalcin retained in bone (29,52). Warfarin treated rats also show a decrease in
osteoclast recruitment and bone resorption (29). Osteocalcin knockout mice show a
decrease in crystal size but an increase in mineral content in their bone (84). This suggests
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that osteocalcin may be involved in resorption-formation coupling and that its presence in
bone may be due to the hydroxyapatite to which it binds. Osteonectin is believed to be
involved, in part due to its high affinity for both hydroxyapatite and calcium ions and for
collagen (29,31,69). The removal of a mineralization inhibitor, such as pyrophosphate or the
glycoprotein decorin, may play a part. Decorin has been shown to be in the uncalcified
osteoid, but not in areas that are mineralized (34).
There are two pathways by which the mineralization of bone can occur, vesicular
mineralization and non-vesicular mineralization (21,31). In both processes, the calcium
crystals grow and elongate parallel to the collagen fibers (11,34). In calcified cartilage and
in woven bone, the osteoblast produces membrane bound vesicles that exocytose from
the plasma membrane, migrate to the matrix, and mineralize from the inside out. As the
enclosed hydroxyapatite crystal grows, it ruptures the vesicle, and continues to
accumulate in size until inhibited (31,34). Mineralization of the crystals appears to be
inhibited by pyrophosphate, adenosine triphosphate (ATP), and by acidic noncollagenous proteins that are also produced by the osteoblast (31).
In lamellar bone, which has the collagen fibers laid at angles on top of each other,
the mineralization does not use vesicles, probably due to space restrictions (31). Here the
mineralization occurs between the collagen fibers and at junctions of collagen and noncollagenous proteins. The mineralization occurs within fibers and expands around them,
oftentimes distorting the collagen fibers (65). The 40 nm “hole” region is also an area of
mineralization, due to the fact that there is available space and possibly due to the high
amount of carbohydrates found covalently attached to the hydroxylysine residues (10,31,51).
The "holes" are thought to form continuous channels that allow for a seam of mineral to
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5-unit microfibril

Formation of continuous channel by “hole” zones

Figure 10. The hole zones of microfibrils align to form seams where mineral
crystals are deposited and grow. The crystals enlarge and push against the fibrils,
distorting them and sometimes embedding themselves into the fibrils. What
initiates crystal deposition and growth are unknown.
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be deposited and grow (28,70). (Figure 10) The stimulus for mineralization in lamellar
bone is not known, but non-collagenous proteins probably play a role since purified
collagen is a poor initiator of mineralization. This may be why collagen fibrils band
together to form fibers prior to mineralization. Acidic non-collagenous proteins appear to
inhibit mineralization of lamellar bone, but available space must also a contributing
factor (31,34). Interestingly, osteonectin, one of the non-collagenous proteins thought to be
involved in mineralization, may also be involved in the inhibition of mineralization.
When bound to collagen, osteonectin promotes the deposition of hydroxyapatite onto the
scaffold surface, but when in solution, osteonectin saturates mineralization sites and
prevents further mineralization possibly by competing with bone for calcium ions (52).
This scenario is also being investigated for other proteins involved in bone, including
osteocalcin and phosphoproteins

(67,71).

The aim of the present study is to assess which biochemical and morphological
characteristics of bone are determining factors for bone strength. Morphological features
include osteon size and number, bone density, and microdamage to bone, while
hydroxyapatite crystallinity, mineral content, collagen content, osteocalcin content and
pyridinium crosslink content are all biochemical features. Some of these issues have
been evaluated in companion studies done by collaborators (72). The work described
within this thesis is focused on the analysis of type-I collagen fractional content and on
the amount of pyridinium crosslinking found in the collagen. Quantification of type-I
collagen, and the pyridinium markers, are then correlated to both tension and shear
fracture resistance. This is done in an attempt to identify the most important factors of
bone strength. The morphological and biochemical characteristics, along with the
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measured fracture resistance, are also correlated to age to determine which, if any,
characteristics change throughout life. Differences in bone based on gender will also be
analyzed, since previous studies have found that bone differs biochemically between
male and female.
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Materials and Methods:

Materials:

HPLC grade water, acetonitrile, ethanol, methanol, acetic acid, and TEA were obtained
from Fisher Scientific (Pittsburgh, PA, USA). Protein sequencing grade PITC was
purchased from Sigma (St. Louis, MO, USA). One ml ampules of constant boiling
hydrochloric acid and amino acid standard solutions were from Pierce (Rockford, IL,
USA). The crystallized form of trans-4-hydroxyproline standard was from Sigma.
Bovine serum albumin was obtained from Sigma. Airgas (Charleston, WV, USA)
supplied the nitrogen and helium gases. 1X phosphate buffered saline (8 g NaCl, 0.2 g
KCl, 1.44 g Na2HPO4, and 0.24 g KH2PO4 in 1.0 L H2O, pH 7.4) was made as needed and
stored at 4˚ C. Metrasystems provided the Pyrilinks  enzyme-linked immunosorbent
assay kits (Mountainview, CA, USA).
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Bone Sample Selection:

Cortical bone samples were removed from the tibia and the femur of cadavers
donated by WVU Health Science / Ruby Memorial Hospital within three days post
mortem. Few restrictions were placed on donors of bone samples. Donors were
restricted to European descent. This was done in an attempt to better reflect the
demographics of the state of West Virginia. African Americans represent only 3-5% of
the state's population while native Americans and Oriental Americans represent 1% or
less. Donors with long term disease, such as cancer or diabetes, were identified by death
records and labeled to further examine sub-populations of the study, although none were
identified in the present studies. Donor population included both sexes with ages ranging
from 50 to 94 years old; median age of the sampled population was 79, from a sample
size of 13.
Bone samples were taken from the medial and lateral cortices of the middiaphysis from both the tibia and the femur (Figure 11). Three pieces of bone were taken
from each site, two for shear and tension fracture tests, and one from between them for
analysis of its biochemical and morphological characteristics. Those samples used in
biochemical analysis were cleansed of soft tissue and trabecular bone. The cortical bone
pieces were then placed in acetone for 8-12 hours and shaken to extract any remaining
lipids. The sample specimens were then freeze dried and milled to a fine powder under
liquid nitrogen in a Spex percussion mill. The powdered bone samples were labeled
according to age and sex of the donor, type of bone, location on the bone surface and
from which leg. Samples were then stored at -80˚ C until used.
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Figure 11
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Figure 11. Cortical bone samples were taken from anterior, lateral, and medial
sites of the mid-diaphysis from human femurs.
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Bone Fracture:

The inability of bone to effectively resist fracture is the essence of osteoporosis.
In this study, two types of mechanically induced fractures were propagated on the bone
slices, tension and shear (Figure 12). From these fractures, two indices of bone strength
were obtained; specimen compliance, (C) and the critical load, (Pq). These indices were
then used to calculate the critical strain energy release rate (Gc), which correlates to
bone's ability to resist fracture. The bone slices had a V-notch cut into them with a Vnotch saw blade; this is where the crack will develop. The slices were then saturated in
0.9% NaCl while mounted on either a tension testing or shear-testing device. A linear
variable displacement transducer and a load cell monitored the displacement and load,
respectively. Crack development is measured by a traveling microscope attached to the
load frame, and by a crack propagation strain gauge. Loading is performed at a rate of
0.002 cm/min. The results for specimen compliance and critical load were reported in the
Ph.D. thesis by Yeni (72). The calculated critical strain energy release rates (Gc) were then
used in comparisons to results obtained from the present studies measuring type-I
collagen amount and pyridinium crosslink content.

Tension

Shear
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Hydrolysis of Bone:

Samples were hydrolyzed by methods according to Valais et al. (45,66). Ten mgs of
powdered cortical bone was placed in a Pierce hydrolysis tube along with 1.0 ml of
6 N hydrochloric acid. Oxygen gas was removed for a clean hydrolysis by alternating
five rounds of vacuum pressure and nitrogen gas. Hydrolysis tubes were sealed under a
reduced pressure of ~600 mm Hg with an Emerson Compressor / Vacuum pump. The
samples were then heated to 108˚ C for 20 hours in a Pierce Reacti-therm heating module
in the absence of light. After the samples were hydrolyzed, two 300 µl aliquots were
taken and dried under a nitrogen stream. One sample was used in the quantification of
pyridinium crosslinks in bone, and the other in the determination of the fractional
composition of type-I collagen per bone sample.
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Derivitization and Quantification of Type-I Collagen:

High performance liquid chromatography (HPLC) is a technique used to separate
molecules by sending them, in solution, through a column packed with particles at a high
pressure. These experiments utilized reverse phase HPLC using octadecylsilane (ODS)
beads to separate phenylthiocarbamyl-labeled amino acids from hydrolyzed cortical bone.
The ODS beads packed throughout the column will separate the derivitized amino acids
based on size and shape as specified by the "R" group. The solvent system used was
composed of two solutions: the aqueous mobile phase, and a washing buffer. Derivitized
bone hydrolysates were redissolved and diluted in the mobile phase and injected through
a port into the HPLC. The ODS beads separated amino acids within the sample as the
mobile phase carried them across the column at a high pressure. After separation, a
detector using UV light absorbance records the PITC-derivitized amino acids by elution
time, and this is matched to the known elution times of specific amino acids. The amount
of the light absorbed and the period of time that the light is absorbed is proportional to
the amount of amino acid present, and this is monitored by the chart recorder. Following
this, the solvent is switched to the washing buffer to elute any residual sample left on the
column, thereby regenerating the column for additional usage. In these studies, the
column was typically replaced following two hundred sample injections. A standard
curve was used to determine an amino acid's amount in an unknown sample.
Hydroxyproline, the amino acid used to determine collagen content, elutes at ~ 4.5
minutes as determined by injecting hydroxyproline alone, and also when mixed with
bovine serum albumin (BSA) hydrolysates. The addition of hydroxyproline to BSA, a
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protein that does not contain hydroxyproline, tested whether hydroxyproline's elution
time was changed in the presence of other PITC-labeled amino acids in order to confirm
that hydroxyproline could be accurately detected.
The derivitization of the free amino acids from the acid hydrolyzed bone was
performed according to the methods described by Bidlingmeyer et al. (74). The nitrogen
dried residue of the 300 µl aliquot of hydrolyzed bone was dissolved in 10 mls of waterethanol-triethylamine (TEA) (2:2:1 ratio), and filtered through a Corning 0.20 micron
cellulose acetate membrane to remove any large mineral crystals that might have
impeded the flow through the column. Five 50 µl samples of the redissolved specimens
were taken and dried in a Savant ISS 100 Speed-Vac Concentrator. Each sample was
then redissolved with 50 µl of PITC-solution (ethanol-water-TEA-phenolisothiocyanate
(PITC) (7:1:1:1 ratio). The amino acids in this solution react to produce
phenylthiocarbamyl derivatives of each amino acid (Figure 13). PITC was used as the
derivitizing agent for its efficiency in enzyme kinetics, derivative stability, and sensitivity
in the detection of amino acids from protein hydrolysates at the pmol level (74). The
derivitization reaction of the samples was run for 30 minutes at room temperature, and
then dried again using the Savant Concentrator and stored at 4˚ C until analysis.
For quantification, the PITC derivitized amino acids were resuspended in the
mobile phase of the HPLC (140 mM sodium acetate solution-water-acetonitrile [90:4:6]
with 0.5 ml TEA added per 1.0 L of solution, then titrated to a pH of 6.35). Glacial acetic
acid was used to adjust the pH of the mobile phase. The mobile phase was degassed for
30 minutes under reduced pressure (≈ 600 mm Hg), and then constantly helium sparged
to remove any remaining larger air bubbles that could "crack" the column or impede the
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flow of the mobile phase. A flow rate of 0.8 ml / minute was used to separate the specific
PTC-amino acids with a pressure across the column between 2000-2500 PSI. After the
sample had passed the detector, the column was cleansed with an acetonitrile-water
solution [60:40] for twenty minutes. Following this, the column was equilibrated by the
mobile phase for twenty minutes prior to the next injection. The HPLC used was a
Waters 600E System Controller with a Nova-pak column (300 mm by 3.9 mm) with a
pore size of 60 Å and a particle size of 4 µm. The PTC-amino acids were detected with a
Waters 486 Tunable Absorbance Detector using a deuterium lamp set at a wavelength of
254 nm and AUFS set at 0.1. A Waters 746 Data Module recorded the deflection of
absorbance and the elution times of samples.
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Standards:

Known amounts of PITC derivitized hydroxyproline were separated by HPLC to
establish a concentration curve for each HPLC based determination of hydrolyzed bone
hydroxyproline content. Amounts of PTC-Hyp as low as 3.0 nanograms were
reproducibly detected, and a linear absorbance range between 10 nanograms and 50
nanograms was used to produce the standard curves. The correlation coefficient (r2) of
the standard curves was typically 0.95 or better. The determination of hydroxyproline
had assay variabilities between 0.0 % and 12.7 % for intraassay (N = 19; mean of 3.89 %;
median 2.40 %) and between 1.6 % and 20.8 % for interassay (N = 10; mean of 8.88 %;
median of 7.55 %).
Hydroxyproline was added to a bovine serum albumin (BSA) solution. BSA is a
protein that does not contain hydroxyproline and the sampled was hydrolyzed and
derivitized as described. This control experiment was performed to determine if other
amino acids affected the detectability, reproducibility, or the retention time of PTChydroxyproline. It's detectability and the reproducibility of the assays were unchanged.
The PTC-hydroxyproline was recorded at similar retention times irrespective of the BSA,
however slight variations of the elution times of all amino acids did occur. These
variations appear to have been the product of column pressure that fluctuated slightly
from day to day for unknown reasons rather than effects from the presence of other
amino acids. Bone samples were diluted prior to injection to an estimated 30 nanograms
of hydroxyproline per 10.0 µl injection. Appropriate dilutions were estimated from the
reports that bone is 35% organic matrix, 90% of which is type-I collagen, and assuming
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that the proportionality constant of hydroxyproline is 0.14 µgs for 1.0 µg of type-I
collagen (45).
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Calculations:
Hydroxyproline
The amount of hydroxyproline per ten milligrams of bone was determined by the
formula:
(N / 1x10 ) x 14.667 = H
-5

Where “N” is the number of nanograms of hydroxyproline in a 10 µl injection as
determined by a standard curve.
“1 x 10 ” is the amount injected (in liters) into the HPLC.
-5

“14.667” is the dilution factor.
“H” is the amount of hydroxyproline in 10.0 milligrams of cortical bone.

Type-I Collagen
The amount of type-I collagen per ten milligrams of bone was then determined by
the formula:
H / 0.14 = C
Where “H” is the amount of hydroxyproline in 10.0 milligrams of bone.
“0.14” is the proportionality constant of hydroxyproline to type-I collagen.
“C” is the amount of type-I collagen in 10.0 milligrams of cortical bone.
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Pyridinium
Pyridinium content in the bone samples was measured by EIA as described in a
following section. The amount of pyridinium per 10 milligrams of cortical bone was
determined by the formula:
X * 6.67 = P
Where "X" is the amount of pyridinium in nanomoles as determined by the standard
curve.
"6.67" is the dilution factor for the EIA.
"P" is the nanomoles of pyridinium per 10 milligrams of cortical bone.

Ratio of Pyridinium to Type-I Collagen
The ratio of pyridinium crosslinks to collagen content is determined by the
equation:
C / 300,000 = moles of Type-I Collagen.
Where "C" is the amount of collagen in milligrams.
"300,000" is the molecular weight of type-I collagen.

moles of Pyridinium / moles of Type-I collagen = Ratio.
This ratio has been estimated to be about 0.3 moles pyridinium per 1.0 mole
collagen in calcified bone (26,57,63,75).
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Critical Strain Energy Release Rate

Fracture resistance for the samples used in the present studies were measured as
described by Yeni (72). Bone's ability to resist fracture is measured as the critical strain
energy release rate for both tension (GIc) and shear (GIIc). This is determined by
measuring the compliance (Cm) as the inverse of the slope of the unloading-reloading
load (P) and the deflection (d) expressed by the formula:
Cm = d/P
The compliance measurements are located at machined designated rate locations 0.254
mm apart from each other. Linear regression analysis was used to calculate compliance
from the unloading-reloading curves by determining the intersection with a line whose
slope is 0.95. The compliance is then used to define the critical strain energy release rate
by the formula used in LEFM:
PQ2
GIc = 
2B

dCm

da

Where "B" is the specimen thickness, "PQ2" is the critical load corresponding to crack
growth, and "dCm / da" is the slope of the curve for compliance vs. crack growth at
specific crack positions. For the femur and tibia, "a" is 8.0 mm (72). GIc and GIIc are used
to describe resistance to tension and shear fracture, respectively, and were related to
collagen and pyridinium amounts found in cortical bone in the present studies.
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Quantification of Pyridinoline and Deoxypyridinoline Crosslinks:

A dried 300 µl sample of hydrolyzed bone was redissolved in 1.0 ml of filtered
Phosphate Buffered Saline (PBS) shielded from light with an aluminum foil wrap, and
stored at -80˚ C until used. Free pyridinoline and deoxypyridinoline crosslinks were
measured using the Metra Biosystems Pyrilinks  assay that has a detection limit of 1.1
nM. Although the Pyrilinks assay is designed to be used clinically to detect pyridinium
in urine, no problems were anticipated in the assay's ability to detect free crosslinks from
hydrolyzed bone, since approximately 70% of pyridinium in urine is peptide bound and
an acid hydrolysis step is needed to generate free crosslinks. The acid hydrolysis step for
urine uses 6 N hydrochloric acid and similar times and temperatures as were used in the
hydrolysis of bone. In the hydrolysis of urine, destruction levels of crosslinks have been
found to vary between 20-60% (75). It is unknown if any degradation of pyridinium
crosslinks occurs by the direct hydrolysis of powdered bone. Both crosslinks have a
combined estimated concentration of 0.3 moles / 1.0 mole of type-I collagen (26, 57, 63).
The Pyrilinks kit is a competitive inhibition assay that uses alkaline phosphotase
conjugated pyridinoline crosslinks with P-nitrophenol-phosphate (PNPP) as the substrate.
Pyridinium crosslinks from the bone samples irreversibly bind to the antibodies on the
plate and remain after washing. An excess of alkaline phosphotase conjugated crosslinks
are then added and binds to all unbound antibodies. After washing off the unbound
enzyme conjugated crosslinks, PNPP is added to the wells and the alkaline phosphotase
activity produces a color change that is measured using the BioRad model 450 microplate
reader. Absorbance was measured at a wavelength of 405 nm. Each sample's absorbance
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was compared with a standard curve (r2 ≥ 0.97) produced for each assay. From these
measurements, the pyridinium content for 10.0 milligrams of cortical bone was
calculated.
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Statistical Analysis:

Statistical analysis of standard curves and predicted values for type-I collagen and
pyridinium crosslinks were determined using a simple linear regression analysis
performed by JMP software (SAS Institute, Cary, N.C.). Standard curves in the HPLC
hydroxyproline assays had a r2 value of 0.95 or greater. Analysis of collagen
concentration and pyridinium content, and their relation to fracture resistance, was done
using a linear and multiple regression analysis by JMP software and Excel software.
Significance was set at Prob. > F = 0.05. Linear regression was used to determine
compliance and LEFM for fracture resistance (72). Intra-assay and inter-assay variabilities
for collagen and pyridinium amounts were determined with each sample's predicted
value, along with standard errors.
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Results:

Type-I collagen's role in bone formation is well documented, although its
relationship to bone strength has not yet been fully determined. Pyridinium crosslinks in
collagen have been found to be excellent markers for bone turnover, but their effect on
bone strength is unclear. In this study, cortical bone from the human femur was tested for
the amount of type-I collagen present in 10.0 milligrams of bone, and the pyridinium
crosslink content of that collagen. Type-I collagen and pyridinium amounts were
compared against bone's resistance to both tension and shear fracture (measured
previously by Yeni (72)), to better understand their roles in bone strength. Type-I collagen
and pyridinium amounts were also analyzed against the age and sex of the bone donor to
determine if any age-related or sex-related differences could be determined; however, the
number of samples per decade varied widely and results should be cautiously interpreted.
Although size, shape, and mass of cortical bone varies by position around the femur,
cortical bone samples from the anterior, lateral and medial sites on the femur were pooled
for collagen amounts. Lateral and medial sites were pooled for pyridinium amounts, and
for tension and shear fracture resistance (9). This group-wise, location pooled data
comparisons were done because the fractional composition of collagen and pyridinium
content in these powdered cortical bone samples were the same (p = 0.26; N = 13, p =
0.16; N = 23; Graph 1; collagen and pyridinium respectively). Data were also analyzed
by sex to determine if the sex of the donor related to the force needed to fracture.
A significant relationship between type-I collagen content and the force needed
for tension fracture was demonstrated (p = 0.046; N = 8; Graph 2). No significant
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relationship between type-I collagen content and shear fracture resistance was identified
(p =0.13; N = 8; Graph 3).
Type-I collagen content was not significantly related to the donors age (p = 0.12;
N = 13; Graph 4), although additional data may alter this conclusion. A previous study
showed that age did significantly correlate with the force needed for both tension and
shear fractures (p = 0.04; N = 28; and p = 0.006; N = 31, respectively) (72). A model
comparing the interaction of the percentage of type-I collagen and the age of donor failed
to show any effect on the force needed for either tension or shear fracture. The
relationship of type-I collagen and age combined, and their effect on tension fracture
resistance and shear fracture resistance were not significant (p = 0.15; N = 8; p= 0.71; N
= 8 respectively).
Male donor derived bone exhibited a higher amount of type-I collagen per ten mg
cortical bone (2.61 ± 0.08 mg, N = 7) than did female derived samples (2.34 ± 0.08 mg,
N = 6) (p = 0.038; N =13; Graph 5). When the combined effect of type-I collagen
amount and the sex of the donor was tested, no influence on fracture resistance was
found. P values for these combined effects (percent collagen and sex of donor) on
tension fracture and on shear fracture were 0.40 (N = 8), and 0.25 (N = 8), respectively.
The amount of pyridinium could not predict the force needed for tension fracture
in pooled samples (p = 0.32; N = 19; Graph 6). However, when sub-dividing the samples
based on sex, pyridinium concentration was predictive for tension fracture resistance in
males (p = 0.048; N = 10), but not in females (p = 0.91; N = 9; Graph 7-A, 7-B).
Interestingly, the combined effects of pyridinium concentration and sex had no
significant effect on bone’s ability to resist tension fracture (p = 0.24; N = 19). Bone-site
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related pyridinium concentrations also showed no relationship to tension fracture
resistance (medial site: p = 0.16; N = 8); lateral site: p = 0.85; N = 11).
Relating pyridinium concentration to shear fracture gave similar results to those
obtained for tension fracture. No correlation existed between pyridinium concentration
and force needed for shear fracture in the pooled samples (p = 0.15; N = 20; Graph 8).
However, in male bone, pyridinium concentration could predict shear fracture resistance
(p = 0.0287; N = 10), but not in females (p = 0.71; N = 10; Graph 9-A, 9-B). No
combinatorial effects of sex and pyridinium concentration on shear fracture were found
(p = 0.60; N = 20). Bone-site pyridinium concentration could not predict shear fracture
force. Medial site samples gave a p = 0.136 (N = 9), while the lateral site gave a p = 0.26
(N = 11).
Pyridinium concentration did not relate to the sex of the donor (p = 0.24; N = 23).
The measured value of pyridinium in female samples was 939 nanomoles ± 72.5 nm /
10.0 milligrams of bone (N = 10) and in males was 823 nanomoles ± 63.5 nm / 10.0
milligrams of bone (N = 13) (Graph 10).
Medial and lateral bone sample pyridinium concentrations were compared.
Pyridinium content in the lateral sample was 945 ± 68 nanomoles and in the medial site
was 808 ± 65 nanomoles (p = 0.16; N = 23; Graph 11). When comparing whether the
site from which the bone slice was removed effected fracture resistance, the results
showed that the force needed for tension fracture was equal between the bone from the
lateral or medial site, (Graph 12-A). Force needed for shear fracture, however, was
measured for the lateral site (Giic = 1657 ± 242; N = 15), and for the medial site (Giic =
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2296 ± 234; N = 16). These data on site-specific force needed for shear fracture only
approached significance (p = 0.07; N = 31; Graph 12-B).
Force needed to fracture was donor-sex related for tension fractures (p = 0.04; N
= 28), but not for shear fracture (p = 0.12; N = 31; Graph 13-A, 13-B). The male
specimens were more resistant to tension fracture forces (72).
No correlation was evident between donor age and bone pyridinium concentration
for all samples (p = 0.63; N = 23; Graph 14). No correlation was seen in the male
samples (p = 0.95; N = 13; Graph 15-A); the data for female bone suggested that
pyridinium concentration may decrease with donor age, although a significant
relationship could not be demonstrated (p = 0.11; N = 10; Graph 15-B). Sample site
analysis also revealed no effect of age to pyridinium concentration.
Collagen and pyridinium content were compared against percent mineral and
crystallinity, two components of the inorganic fraction of bone. Collagen content was
significantly correlated to crystallinity (an indice of crystal size and perfection) (p = 0.04;
N = 7; Graph 16). Collagen content did not relate to percent mineral content (p = 0.135;
N = 7; Graph 17). Pyridinium did not relate to crystallinity (p = 0.92; N = 9) nor to
percent mineral (p = 0.42; N = 9) (Graph 18-A, 18-B). For both tension and shear types
of fracture, the ratio of pyridinium to collagen showed no ability to predict bone strength
for tension fracture (p = 0.96; N = 8); nor for shear fracture (p = 0.27; N = 8) (Graph 19A, 19-B). However, when the combined effect of collagen and pyridinium were
compared against fracture resistance, an indication of a relationship appeared for tension
fracture (p = 0.066; N = 8; Graph 20). This relationship was not seen in shear fracture (p
= 0.126; N = 8). Comparing the pyridinium:collagen ratio to the sex of the donors also
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provided an indication of a potentially significant correlation (p = 0.06; N = 10) with the
ratio in females equal to 0.117 ± 0.012, and in males 0.083 ± 0.01 (Graph 21). The age
of the donor had no effect on the ratio of pyridinium to collagen (p = 0.20; N = 10; Graph
22).
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Collagen Fractional Amount by Location on Femur
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Graph 1. Collagen fractions (mgs/ 10.0 mgs cortical bone) did not
vary significantly by site from which the bone was removed (p = 0.26;
N = 13).
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Type-I Collagen Content by Tension
Fracture
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Graph 2. Type-I collagen (mgs/ 10.0 mgs bone) and its effect on force
required for tension fracture. The data were statistically significant (p =
0.046; N = 8).
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Type-I Collagen Content by Shear
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Graph 3. Type-I collagen (mgs/ 10.0 mgs bone) and its effect on force
required for shear fracture. The relationship was not significant (p = 0.138;
N = 8).
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Type-I Collagen Content by Age
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Graph 4. With increasing age, the fractional amount of type-I
collagen in the femoral cortical bone appears to decrease. However,
the data only approached significance (p = 0.12; N = 13).

100

52

Type-I Collagen Content by Sex
Collagen By Sex
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Graph 5. Type-I collagen content (mgs/ 10.0 mgs of cortical bone) from the
femur was significantly related to the sex of the donor (p = 0.038; N = 13).
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Pyridinium Content by Tension Fracture
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Graph 6. Pyridinium content (nmol/ 10.0 mgs bone) showed no
correlation to the force required for tension fracture in cortical bone of the
femur shaft. Data represents all donors sampled (p = 0.32; N = 19).
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Pyridinium Content verse Tension Fracture by Gender
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Graph 7-A.
Pyridinium content (nmol/ 10.0 mgs bone) predicted tension
fracture in males donors (p = 0.048; N = 10), but not in females donors (Graph 7-B)
(p = .91; N = 13).
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Pyridinium Content by Shear Fracture
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Graph 8. Pyridinium content (nmol/ 10.0 mgs bone) showed no correlation
to force required for shear fracture in all samples (p = 0.15; N = 20).
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Pyridinium Content verse Shear Fracture by Gender
Graph 9-A
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Graph 9-A.
Pyridinium content (nmol/ 10.0 mgs bone) predicts fracture
resistance in the males sub-group (p = 0.029; N = 10), but not in the female subgroup (Graph 9-B) (p = 0.71; N = 10)
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Pyridinium Content by Sex
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Graph 10. Pyridinium crosslink content (nmol/ 10.0 mgs bone)
showed no significant correlation to the sex of the donor (p = 0.24; N
= 23).
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Pyridinium Content by Location on Femur
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Graph 11.
The location of the bone sample from the femur did
not correlate to pyridinium crosslink content (p = 0.16; N = 23). The
anterior site had a significantly lower pyridinium content (nmol/ 10.0
mgs bone) (data not shown).
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Bone Fracture by Location on Femur
Graph 12-A
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Graph 12-A.
Location of bone sample had no effect on tension fracturing. However,
for shear fracture the lateral site had a much lower force requirement for fracture which
approached significance (p = 0.07; N =30). The cause for this is unknown.
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Fracture Resistance by Gender
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Graph 13-A
Males require more force for tension fracture the bone than
females (p = 0.04; N = 28). The data did not reach significance when shear
fracture was tested (p = 0.12; N = 31) (Graph 13-B).

61

Pyridinium by Age of Donor
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Graph 14.
Pyridinium content (nmol/ 10.0 mgs bone) showed
no relationship to the age of the donor (p = 0.63; N = 23).
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Graph 15-A
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Graph 15-A. Male donors show no decrease in pyridinium content
with increasing age. The data from female donors suggest a possible
decrease in crosslink content with increasing age, (Graph 15-B),
however these data did not reach significance (p = 0.11; N = 10).
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Collagen Content by Crystallinity and
Percent Mineral
Graph 16
Collagen

vs

Crystallinity

(1/B)

R2 = 0.5992
P Value = 0.0411

2.4

2.7

0.03
0.028

Crystallinity (1/B)

0.026
0.024

0.022
0.02
0.018

0.016
0.014
1.5

1.8

2.1

3

Type-I Collagen per 10.0 mgs Cortical Bone

Graph 17
Collagen vs % Mineral

R2
= 0.3875
P Value = 0.1354

65
60

55

% Mineral

50

45
40
35

30
25
1.5

1.7

1.9

2.1

2.3

2.5

2.7

2.9

Type-I Collagen per 10.0 mgs Cortical Bone

Graph 16. Collagen content showed a significant correlation to crystallinity (p = .04; N = 7).
Graph 17. Collagen content did not correlate to percent mineral content (p = 0.135; N = 7).
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Pyridinium Content by Crystallinity and
Percent Mineral
Graph 18-A
2

Pyridinium

vs

R = 0.0015
P value = 0.92

Crystallinty

0.026

0.024

0.02

0.018

0.016

0.014

0.012

0.01
0

200

400

600

800

Nanomoles

of

1000

1200

1400

Pyridinium

Graph 18-B
2

Pyridinium

vs

%

R
= 0.0948
P value = 0.42

Mineral

60

55

50

% Mineral

Crystallinity (1/B)

0.022

45

40

35

30

25
0

200

400

600
Nanomoles

800
of

1000

1200

1400

Pyridnium

Graph 18-A.
Pyridinium content did not correlate to crystallinity (p = 0.92; N = 9) nor
to percent mineral content (p = 0.42; N = 9), (Graph 18-B).
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Pyridinium:Collagen Ratio Effect on
Tension and Shear Fracture
Graph 19-A
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Graph 19-A.
The ratio (in moles) of pyridinium to collagen showed no relationship
to tension fracture (p = 0.96; N = 8) nor to shear fracture (Graph 19-B) (p = 0.27; N = 8).
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Synergistic Response of Pyridinium and
Collagen and their Effect on Tension
Fracture
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Graph 20. The synergistic response of pyridinium and collagen showed a
potential correlation to tension fracture (p = 0.066; N = 8). If this can be
confirmed it will show that pyridinium does have an effect on collagen and
bone strength.
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Pyridinium:Collagen Ratio vs Sex of
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Graph 21.
The ratio of pyridinium to collagen (in
moles) approached significance (p =0.06; N = 10).
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Pyridinium:Collagen Ratio vs Age of
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Graph 22.
The ratio of pyridinium to collagen (in moles) had no
relationship to the age of the donor (p = 0.2; N = 10).
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Discussion

To effectively treat osteoporosis, the components that contribute the most to bone
strength must be identified so that therapies can better target them. This study, which
compliments work previously reported by Yeni, examined potential relationships
between type-I collagen content and the amount of pyridinium crosslinks of collagen to
bone's ability to resist fractures (72). Yeni analyzed osteon size and number, bone mineral
content and quality, microdamage to bone, and the porosity of bone in an attempt to
identify the important biological and morphological contributions of cortical bone to
fracture resistance. These combined studies are expected to provide a better
understanding of these parameter's contributions to bone's overall strength.
The amount of type-I collagen had a significant, direct relationship to tension
fracture (p = 0.046; N = 8). An estimated 90% of the protein infrastructure of bone is
comprised of type-I collagen. This collagen-based infrastructure forms the framework
upon which non-collagenous proteins are fixed and mineral crystals are deposited and
grow. A lower percentage of collagen makes for a leaner scaffold upon which mineral
crystals can be deposited, which could cause bone to have a lower bone mineral density
(BMD). This defines osteopenia, representing a weakened, low BMD bone. Once a
fracture occurs, this bone is termed osteoporotic. Since bone is a composite material its
strength is derived from the combined properties of the protein matrix and the associated
hydroxyapatite mineral. The collagen fiber framework is not completely rigid, but allows
some bending and flexing which accommodates the deposition and growth of
hydroxyapatite crystals. The mineral crystals normally elongate parallel to the direction
of the fibers. As the crystals increase in length and width, they push against, distort, and
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embed themselves into the collagen fibers. Once the fibrous scaffold becomes
mineralized, the bending and flexing of the framework is limited. In cortical bone,
available space appears to be a controlling factor in mineral crystal growth. Larger
hydroxyapatite crystals have been found to be more brittle than smaller crystals (11,28,78).
A lower amount of collagen allows more space for the mineral crystals to grow. If a low
collagen content caused a lower BMD with larger, more brittle hydroxyapatite crystals
the bone would be predisposed to fracture. This weakening of bone was seen in the
results for tension fracture, where bone with less collagen content required less force to
fracture. However, even though a significant relationship was seen, due to the relatively
low number of test subjects examined, this data may yet be considered preliminary. A
cautious view is appropriate since one sample from a 94-year-old donor had a much
lower content of collagen than did the other specimens measured, along with the lowest
amount of force required for tension fracture.
When collagen content and pyridinium amount were compared together against
tension fracture, the data are suggestive of a relationship that might be confirmed through
extended studies, (p = 0.066; N = 8). The pyridinium crosslinks are thought to aid in the
packing of collagen monomers into fibrils and orientating fibrils into fibers. If a
relationship between collagen and pyridinium to tension fracture should be confirmed, it
will indicate that pyridinium content of bone plays a role in bone strength, possibly
through modulating the proper formation and correct orientation of collagen fibers in
bone.
Collagen content alone did not predict shear fracture resistance (p = 0.13; N = 8).
When collagen content and pyridinium amount were compared together against shear
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fracture, the data did not predict bone strength although the data may suggest a potential
relationship (p = 0.126; N = 8). Further study may show a significant relationship to
shear fracture resistance. This putative relationship may relate to the type of fracture
assessed, since the forces used in shear fracture induce a sliding along the collagen fiber
length as opposed to the pulling apart of bone which is measured as tension fracture.
Since the pyridinium crosslinks connect collagen monomers to each other, and connect
collagen fibrils together, perhaps during shear fracture the crosslinks help maintain
individual fiber position and oppose the sliding of fibers along one another.
Collagen is vital to bone strength (10,11,27,33,36,40-42,48). Numerous diseases affect
collagen, and as a consequence, effect bone and other collagen rich tissues. Osteogenesis
Imperfecta (O.I.), first described in the eighteenth century, is one of the most studied
collagen-based diseases (11,27,36,40,41). Its severity can vary from mild to lethal in utero.
Several mutations in the collagen genes have been identified that cause the many variants
of O. I. Mutations that cause shortened procollagen sub-units, homotrimers of collagen,
or bent collagen triple helices, are known. Most collagen in O. I. forms thin, abnormal
fibers, possibly caused by excessive hydroxylation and glycosylation after translation of
the protein. These abnormal fibers produce a malformed bone which the body attempts
to remodel, often at an accelerated pace. Although the studies on O. I. have shown
collagen's importance to bone formation and its inherent strength, they are all done on
genetically abnormal collagen. More recent studies have looked at normal collagen and
its effect on bone strength, specifically dealing with osteoporosis. Areas of inquiry have
focused on collagen's orientation in bone, collagen's interaction with non-collagenous
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proteins, the association between matrix and mineral, and biochemical changes in
collagen as one ages (2,4,7,9,10,13,24,28,34,48,58).
From the present study, it is seen that a decrease in collagen content correlates
with a decrease in bone strength. This agrees with several studies that have linked the
content of collagen in bone to its resistance to fracture (11,78). Bailey et al. found a strong
correlation between collagen content and maximum stress levels, (σmax), Young's
modulus, (ε) (which is the maximum slope of the stress-strain curve) and the energy
absorption level, (ωabs), during mechanical compression (78).
With age, and after the menopause, bone mass decreases. The present study
tested whether the percentage of type-I collagen decreased with increased age. A
relationship was suggested in the present study, however this putative relationship could
not yet be confirmed, (p = 0.12; N = 13). This trend approached significance even
though donors that took antiresorptive agents to aid in arresting bone loss were not
excluded from the study and were not identified for these studies. This could be
important because the age of the donors showed a very strong correlation to fracture
resistance (tension fracture p = 0.037; N = 28; shear fracture p = 0.006; N = 31) (72). Age,
and its likely effects on collagen content and overall bone mass, apparently correlates
with bone strength. However, when age and collagen content together were compared
against tension or shear fractures, no significant relationship could be demonstrated. This
was unexpected and the low sample number assessed may have compromised this
outcome. Since collagen amount seems to predict bone strength, as does age, together
they were expected to show an even stronger correlation to bone strength. Bone's
decrease in collagen content with respect to age agrees with several related studies that

73
have shown similar results (76,77,78). This decrease in collagen content may be due to the
imbalance in the highly coupled process of resorption and formation. Beginning at
around age 40 for cortical bone, a slow age-dependant loss of bone occurs. This loss of
bone is believed to be a result of normal resorption, with a failure of the osteoblasts to
completely refill the resorption pits. Little is known about the decrease in efficiency of
the osteoblasts, though a decrease in quality and quantity of type-I collagen production is
a distinct possibility. Coupled with the postmenopausal phase of rapid bone loss due to
an increase in the rate of bone resorption, and the reason for the age related decrease in
bone strength in women seems evident.
Significant results indicating sex-linked characteristics were obtained for type-I
collagen content (p = 0.038; N = 13). Males averaged 2.61 milligrams ± 0.08 of collagen
per 10.0 milligrams of cortical bone (average age 75), while women had a lower collagen
quantity, 2.32 milligrams ± 0.09 (average age 85). However these data should be
considered preliminary due, again, to the low number of test subjects and the possibility
that age contributed to the effect. As to the sexually dimorphic differences in collagen
content of bone, there are known differences in the skeletal system between men and
women, and it seems likely that collagen production could have differences also. Barring
disease, males typically attain a higher peak bone mass than do females, and females,
after the menopause, lose bone at a faster rate than males (17). The linear growth of bone
continues till about the age of twenty, while its radial growth continues until age thirty.
Growth is then followed by a slow, continual decrease in bone mass. It is estimated that
the age dependant phase of bone loss begins at age thirty-five for trabecular bone, and at
age forty for cortical bone, and that this bone loss continues up until death (14). It is
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believed that men and women lose similar amounts of bone during this phase. This loss
has been estimated to be about twenty-five percent of both trabecular and cortical bone
over a lifetime (14). Women, however, go through another rapid phase of bone loss that
begins at the onset of menopause. This phase of bone loss can be ameliorated by
estrogen replacement therapy. In the absence of therapy an additional ten percent loss of
cortical bone and an additional twenty-five percent loss of trabecular bone in women may
occur (14,29). Thus, the issues raise the question of whether the differences in collagen
content between males and females are an artifact due to the average age of donors
sampled, or might accurately reflect a limited collagen production by females in attaining
peak bone mass, or be a consequence of the increase in bone resorption in postmenopausal females which is followed by the formation of new bone whose quality and
quantity may be compromised. Donor sex also had a significant relationship to tension
fracture (p = 0.042; N = 31), perhaps due to collagen content.
When pyridinium content was compared to sex, no trend was apparent (p = 0.24;
N = 23). The female samples averaged 940 nanomoles ± 72 nm of pyridinium per 10.0
milligrams of cortical bone, giving a molar ratio of pyridinium to collagen of 0.12. Male
donors averaged 823 nanomoles ± 64 nm of pyridinium for a molar ratio of 0.08. When
taken as a molar ratio, women appear to have a more highly cross-linked collagen
scaffold, with one half more pyridinium crosslinks per mole of collagen, than did men.
This difference approached statistical significance (p = 0.06; N = 10). A larger sample
size may provide the data to make a definite conclusion. Although both men and women
in this study have a lower molar ratio of pyridinium to collagen than that which has been
previously reported, this may be due to the possible degradation of pyridinium during the
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acid hydrolysis of bone and the lack of valid comparisons between EIAs and other
methods that have been used for detection (61,75). Another possibility is that there is a
loss of pyridinium crosslinks as a consequence of a loss of mature bone with age
resulting in a decreased ratio of pyridinium to collagen.
No significant relationship was observed when comparing the pyridinium to
collagen ratio against tension fracture (p = 0.96; N = 8). When relating this ratio to shear
fracture, again no significance was observed (p = 0.27, N =8). This was surprising since
it was expected that pyridinium crosslinks would help orientate and stabilize the collagen
fibers, and thus strengthen bone. Also the synergistic effect of collagen and pyridinium
on both tension and shear fracture approached significance. Relating the molar ratio of
pyridinium to collagen to the age of the donors showed no significant correlation.
It was assumed that there would be no biochemical differences in collagen with
respect to the site from which bone was removed, and indeed the non-reducible crosslink
content did not statistically differ between the lateral site and medial site of the femur
shaft (p = 0.16; N = 23). When all samples of pyridinium were related to the age of the
donors, no correlation was observed (p = 0.625, N = 23). Interestingly, when dividing
the donors by sex, age may effect pyridinium content in females, although this effect
could not be shown to be significant in the present study (p = 0.11; N = 10). This trend
was not evident in males (p = 0.95; N =13).
If the decrease in mature pyridinium crosslinks in females could have been
demonstrated, such results would disagree with several studies that have found no change
in pyridinium levels as age increases (48). However, not all studies separated the donors
according to gender. An age related decrease in mature crosslinks might be a reasonable
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expectation due to the increased resorption rate seen in post-menopausal females. A
decrease in older, more mature bone would correlate to a decrease in mature nonreducible pyridinium crosslinks.
When relating pyridinium content to tension fracture, no significant correlation
could be attributed when all samples were pooled (p = 0.32; N =19). However, a gender
specific response was observed. Pyridinium content directly correlated to force required
for tension fracture in males (p = 0.0478, N = 10). This was not seen in female donors (p
= 0.91; N = 9). In looking at shear fracture, similar results were apparent. With samples
from both genders pyridinium content did not predict shear fracturing (p = 0.1526; N =
20). The female sub-group showed no significance (p = 0.71; N = 10), but pyridinium
content did correlate to force required for shear fracture in the males (p = 0.029; N = 10).
These results appear to follow previous studies on pyridinium content and its lack of
effect on bone strength, but also pose new questions concerning possible gender-related
differences in the non-reducible collagen crosslinks of bone.
Bailey et al. (48) studied biochemical differences in collagen from the head and
neck regions of the human femur in young, old, and osteoporotic bone. They reported
that the hydroxylation of lysine was similar between young and old bone, but was much
higher in osteoporotic bone. The increase in lysyl hydroxylation was more apparent in
the head region of the femur, although both regions were different in the osteoporotic
samples. They also compared the reducible crosslink hydroxylysino-5-ketonorleucine
(HLKNL) and the non-reducible crosslink, pyridinoline, between normal and
osteoporotic bone. The divalent HLKNL was found to be reduced 20% in the head
region, and by 44% in the neck in osteoporotic bone, while the mature trivalent
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pyridinoline remain the same between young, old, and osteoporotic bone in both the head
and neck region of the femur. Bailey et al. had only thirteen donors in their study and
sub-division by gender was not done, nor was any analysis of fracture resistance.
Bailey et al. continued with another study in which they found a decrease in
collagen content with age (76). They also confirmed earlier studies reporting an increase
in hydroxylation of lysine and a decrease in reducible crosslinks in osteoporotic bone.
They failed to determine if the increase in lysyl hydroxylation caused a difference in ratio
of dihydrolysinonorleucine and hydrolysinonorleucine. They also did not determine if
the increase in lysyl hydroxylation changed the ratio of pyridinoline to
deoxypyridinoline.
Bätge et al. (24) compared biochemical differences of collagen from trabecular
bone of the vertebrae from normal and osteoporotic patient's. Bätge observed an increase
in the hydroxylation of lysine on the α(2)-I chain of collagen correlated to decreases in
the vertebral bone mass and the vertebral trabecular bone volume. The hydroxylation of
lysine on the α(1)-I chain remained the same for all samples. Similar results were
obtained when sub-dividing the samples by gender. No correlation could be attributed
between lysyl hydroxylation and the age of the female donors; however differences were
found between pre-menopausal donors, post-menopausal donors, and those with
established osteoporosis. Bätge does not discuss pyridinium crosslinks, nor how they
could be affected by an increase in lysyl hydroxylation on the α(2)-I sub-unit. The ratio
of crosslinking appears to be 3.5:1.0 for α(1)-I to α(2)-I sub-units, so the increase in
hydroxylation of the α(2)-I sub-unit may not effect cross-linking as much as it would if it
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occurred in the α(1)-I sub-units (50). Bätge also looked at trabecular bone from the
vertebrae, thus those differences may not apply to cortical bone from the femur.
Oxlund et al. (77) studied trabecular bone from vertebral samples from normal and
osteoporotic patients. They found an age-related decrease in collagen density (mg
collagen / cm3) but no difference between normal and osteoporotic patients. Both
divalent crosslinks were found to be reduced in osteoporotic patients but not the nonreducible trivalent pyridinium crosslinks. This agrees with Bailey and Bätge, and may be
explained by the fact that the divalent crosslinks outnumber the mature trivalent
crosslinks 2-4 to 1. Large decreases of these reducible crosslinks could dramatically
reduce the strength of the newly formed bone, and thus the strength of the entire bone,
without changes in the pyridinium crosslink concentration. Oxlund et al. also state that
they found no change in pyridinium content with respect to age, but provide no data.
Lo Cascio et al. (5) found an increase in urinary GHYLin post-menopausal
osteoporotic women compared to post-menopausal normal women. The increase in
urinary GHYL may be a result of remodeling at the fracture sites as opposed to an overall
increase during the normal production of collagen. No differences were found in the
urinary excretion of pyridinium crosslinks between osteoporotic and normal women.
However, this may indicate that the rate of bone resorption was similar between the two
groups, and is not a measure of the actual pyridinium amounts of bone.
Köwitz et al. (58) studied osteoporotic, osteoarthritic, and normal women, and
compared lysyl and prolyl hydroxylation between the three groups. They found an over
hydroxylation of lysine in both alpha sub-units in the cortical and trabecular bone in the
neck region of the human femur, and in trabecular bone in the femur head in the
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osteoporotic group. Lysyl hydroxylation was similar between the osteoarthritic and
normal group. Prolyl hydroxylation was found to be similar in all compartments of bone
between all three subgroups. Over modification of lysine in collagen is believed to occur
during the repair of fractures (5). Köwitz, however, took bone within two days of fracture
to eliminate any increase due to fracture healing. Because of this, they believe the
observed increase in lysine hydroxylation precedes osteoporosis and is not a consequence
of the disease. Whether the increase in hydroxylation causes changes in the formation of
mature crosslinks is unknown. It is known that bone and cartilage contain a higher
number of hydroxylysine residues in the telopeptide regions of collagen than does the
collagen of skin. This predisposes the formation of pyridinium crosslinks in bone. In
skin, lysyl oxidase acts more on lysine residues in the telopeptide regions, resulting in the
formation of histidine crosslinks (57). Perhaps the increase in hydroxylation changes the
ratio of pyridinoline to deoxypyridinoline in bone or the ratio of pyridinium to collagen.
Another possibility is that the increased hydroxylation changes the amount of
glycosylation to lysine residues in collagen, which in turn may effect collagen fiber
formation, crosslinking, and/or mineralization.
Pyridinium crosslinks are known to be important for correct bone formation from
several studies on Ehler Danlos Syndrome and lathyrism. These studies have shown that
proper crosslinking is an important determinant of bone strength. Why pyridinium
content predicts fracture resistance in men is unknown. Though not confirmed in this
study, the possibility that males may have less pyridinium crosslinks than females can be
raised. Also the ratio of pyridinium to collagen may have importance to bone strength.
Perhaps these mature crosslinks only play a role in strengthening bone when they are
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present in a limited amount. This possibility may warrant continued research of this type,
although this is not a finding seen in other studies (76,77,78).
In conclusion, type-I collagen content appears to be a determinant of bone
strength, specifically in tension fracture resistance. Collagen content may decrease with
patient age, though this was not confirmed. Also shown in this study is that collagen may
have gender-specific differences. These may include fractional composition of bone and
the ratio of pyridinium to collagen, which may relate to bone strength. Others have
shown that not only is the quantity of collagen important, but the quality of the protein
also contributes to bone strength. The biochemical changes in collagen as age increases
include increased hydroxylation of lysine, increased glycosylation of the sub-units, and a
decrease in reducible divalent crosslinks. How these parameters may effect the mature
trivalent pyridinium crosslinks remains unknown. This study also suggests that the
amount of pyridinium crosslinks may have specific gender differences, and this may
relate to the age of the donor and to bone strength.

81
References

1.

Kanis, J.A., Melton, III, L.J., Christiansen, C., Johnston, C.C., Khaltaev, N. The
Diagnosis of Osteoporosis. J. Bone Miner. Res. 9-8 pp 1137-1141, 1994.

2.

Parisien, M., Cosman, F., Mellish, R.W.E., Schnitzer, M., Nieves, J., Silverberg,
S.J., Shane, E., Kimmel, D., Recker, R.R., Bilezikian, J.P., Lindsay, R.,
Dempster, D.W. Bone Structure in Postmenopausal Hyperthyroid, Osteoporotic,
and Normal Women. J. Bone Miner. Res. 10-9 pp 1393-1399, 1995.

3.

Marcus, R.: 'Organizational and Functional Aspects of Skeletal Health' in
Osteoporosis (ed. Marcus), Blackwell Scientific Publications, Boston, Mass. pp 116, 1994.

4.

Dempster, David W. The Contribution of Trabecular Architecture to Cancellous
Bone Quality. J. Bone Miner. Res. 15-1 pp.20-23, 2000.

5.

Lo Cascio, V., Bertoldo, F., Gambaro, G., Gasperi, E., Furlan, F., Colapietro, F.,
Lo Cascio, C., Campagnola, M., Urinary Galactosyl-Hydroxylysine in
Postmenopausal Osteoporotic Women: A Potential Marker For Bone Fragility. J.
Bone Miner. Res. 14-8 pp. 1420-1424, 1999.

6.

Melton, L.J., Chrischilles, E.A., Cooper, C., Lane, A.W., Riggs, B.L. How Many
Women Have Osteoporosis. J. Bone Miner. Res. 7-9 pp 1005-1010, 1992.

7.

Aerssens, J., Van Audekercke, R., Geusens, P., Schot, L.P.C., Osman, A.,
Dequeker, J. Mechanical Properties, Bone Mineral Content, and Bone
Composition (Collagen, Osteocalcin, IGF-I) of the Rat Femur: Influence of
ovariectomy and Nondrolone Decanoate (Anabolic Steroid) Treatment. Calcif.
Tissue Int. 53 pp. 269-277, 1993.

8.

Kimmel, D. B., Recker, R. R.: 'Clinical Assessment of Bone Strength' in
Osteoporosis (ed. Marcus), Blackwell Scientific Publications, Boston, Mass. pp
49-68, 1994.

9.

Bell, K. L., Loveridge, N., Power, J., Garrahan, N., Stanton, M., Lunt, M.,
Meggitt, B. F., Reeve, J.: Structure of the Femoral Neck in Hip Fracture:
Cortical Bone Loss in the Inferoanterior to Superoposterior Axis. J. Bone Miner.
Res. 14-1 pp. 111-119, 1999.

10.

Puustjärvi, K., Nieminen, J., Räsänen, T., Hyttinen, M., Helminen, H. J., Kröger,
H., Huuskonen, J., Alhava, E., Kovanen, V.: Do More Highly Organized
Collagen Fibrils Increase Bone Mechanical Strength in Loss of Mineral Density
After One-Year Running Training? J. Bone Miner. Res. 14-3 pp. 321-329, 1999.

82
11.

Boskey, A. L., Wright, T. M., Blank, R. D.: Collagen and Bone Strength. J. Bone
Miner. Res. 14-3 pp. 330-335, 1999.

12.

Uzawa, K., Grzesik, W. J., Nishiura, T., Kuznetsov, S. A., Gehron Robey, P.,
Brenner, D. A., Yamauchi, M.: Differential Expression of Human Lysyl
Hydroxylase Genes, Lysine Hydroxylation, and Cross-linking of Type I Collagen
During Osteoblastic Differentiation In Vitro. J. Bone Miner. Res. 14-8 pp. 12721280, 1999.

13.

Ciarelli, T. E., Fyhrie, D. P., Schaffler, M. B., Goldstein, S. A.: Variations in
Three-Dimensional Cancellous Bone Architecture of the Proximal Femur in
Female Hip Fractures and in Controls. J. Bone Moner. Res. 15-1 pp. 32-40, 2000.

14.

Riggs, B. L.: Overview of Osteoporosis. Western Journal Med. 154 pp 63-77,
1991.

15.

Arnaud, C.D. : Osteoporosis: Using "Bone Markers" for Diagnosis and
Monitoring. Geriatrics 53 pp 24-30, 1996.

16.

Garnero, P., Hausherr, E., Chapuy, M.-C., Marcelli, C., Grandjean, H., Muller, C.,
Cormier, C., Bréart, G., Meunier, P.J., Delmas, P.D.: Markers of Bone
Resorption Predict Hip Fracture in Elderly Women: The EPIDOS Prospective
Study. J. Bone Miner. Res. 11-10 pp 1531-1538, 1996.

17.

Kohrt, W.M., Snead, D.B., Slatopolsky, E., Birge, Jr., S.J. : Additive Effects of
Weight-Bearing Exercise and Estrogen on Bone Mineral Density in Older
Women. J. Bone Miner. Res. 10-9 pp 1303-1311, 1995.

18.

Mundy, G. R. : 'Bone Resorbing Cells' in Primer on Metabolic Bone
Diseases and Disorders of Mineral Metabolism : 2nd Edition (ed. Fauvus), Am.
Soc. Bone Miner. Res., Kelseyville, CA. pp 25-32, 1993.

19.

Price, C.P. : Case Studies in Metabolic Bone Disease: Assessing the
Potential for Biochemical Markers. LabMedica International 8-1, 1996.

20.

Roodman, G.D. : Advances in Bone Biology: The Osteoclast. Endo Rev. 17-4 pp
308-332, 1996.

21.

Jilka, R. L., Manolagas, S. C.: 'The Cellular and Biochemical Basis of Bone
Remodeling' in Osteoporosis (ed. Marcus), Blackwell Scientific Publications,
Boston, Mass. pp 17-47, 1994.

22.

Öz, O. K., Zerwekh, J. E., Fisher, C., Graves, K., Nanu, L., Millsaps, R.,
Simpson, E. R.: Bone Has a Sexually Dimorphic Response To Aromatase
Deficiency. J. Bone Miner. Res. 15-3 pp. 507-514, 2000.

83
23.

Faulkner, K. G.: Bone Matters: Are Density Increases Necessary to Reduce
Fracture Risk? J. Bone Miner. Res. 15-2 pp. 183-187, 2000.

24.

Bätge, B., Diebold, J., Stein, H., Bodo, M., Müller, P. K.: Compositional Analysis
of the Collagenous Bone Matrix. A Study on Adult Normal and Osteopenic Bone
Tissue. Euro. J. Clin. Invest. 22 pp. 805-812, 1992.

25.

Melton III, L. J., Atkinson, E. J., O'Connor, M. K., O'Fallon, W. M., Riggs, L. B.:
Determinates of Bone Loss from the Femoral Neck in Women of Different Ages.
J. Bone Miner. Res. 15-1 pp. 24-31, 2000.

26.

Calvo, M.S., Eyre, D.R., Gundberg, C.M. : Molecular Basis and Clinical
Application of Biological Markers of Bone Turnover. Endocr. Rev. 17-4 pp.
333-368, 1996.

27.

Baron, R. : 'Anatomy and Ultrastructure of Bone' in Primer on Metabolic Bone
Diseases and Disorders of Mineral Metabolism : 2nd Edition (ed. Fauvus), Am.
Soc. Bone Miner. Res., Kelseyville, CA. pp 3-9, 1993.

28.

Landis, W. J.: The Strength of a Calcified Tissue Depends in Part on the
Molecular Structure and Organization of its Constituent Mineral Crystals in their
Organic Matrix. Bone 16-5 pp. 533-544, 1995.

29.

Ingram, R.T., Park, Y.K., Clarke, B.L., Fitzpatrick, L.A. : Age- and
Gender-Related Changes in the Distribution of Osteocalcin in the Extracellular
Matrix of Normal Male and Female Bone. J. Clin. Invest. 93 pp 989-997, 1994.

30.

Puzas. J.E. : 'The Osteoblast' in Primer on Metabolic Bone Diseases and
Disorders of Mineral Metabolism : 2nd Edition (ed. Fauvus), Am. Soc. Bone
Miner. Res., Kelseyville, CA. pp 15-21, 1993.

31.

Termine, J.D. : 'Bone Matrix Proteins and the Mineralization Process' in Primer
on Metabolic Bone Diseases and Disorders of Mineral Metabolism : 2nd Edition
(ed. Fauvus), Am. Soc. Bone Miner. Res., Kelseyville, CA. pp 21-25, 1993.

32.

Wright, G. M., Leblond, C. P. : Immunohistochemical Localization of
Procollagens. J. Histochem. Cytochem. 29-7 pp 791-804, 1981.

33.

Burgeson, R.E., Nimni, M.E. : Collagen Types : Molecular Structure and Tissue
Distribution. Clin. Ortho. Related Res. 282 pp 250-271, 1992.

34.

Hoshi, K., Kemmotsu, S., Takeuchi, Y., Amizuka, N., Ozawa, H.: The Primary
Calcification of Bone Follows Removal of Decorin and Fusion of Collagen
Fibrils. J. Bone Miner. Res. 14-2 pp. 273-280, 1999.

84
35.

Canalis, E. : 'Regulation of Bone Remodeling' in Primer on Metabolic Bone
Diseases and Disorders of Mineral Metabolism : 2nd Edition (ed. Fauvus), Am.
Soc. Bone Miner. Res., Kelseyville, CA. pp 33-37, 1993.

36.

Prockop, D. J., Kivirikko, K. I.: Heritable Diseases of Collagen. New
England J. Med. 311-6 pp 376-385, 1984.

37.

Cheah, K. S. E.: Collagen Genes and Inherited Connective Tissue Disease.
Biochem. J. 229 pp 287-303, 1985.

38.

Prockop, D.J., Kadler, K.E., Hojima, Y., Constantinou, C.D., Dombrowski, K.E.,
Kuivaniemi, H., Tromp, G., Vogel, B. : Expression of Type I Procollagen Genes.
Ciba Foundation Symposium 136, pp 142- 160, 1988.

39.

Teitelbaum, S. L. : 'Molecular Defects in Bone Developement' in Primer on
Metabolic Bone Diseases and Disorders of Mineral Metabolism : 2nd Edition (ed.
Fauvus), Am. Soc. Bone Miner. Res., Kelseyville, CA. pp 10-15, 1993.

40.

Bonadio, J., Goldstein, S.A.: 'Our Understanding of Inherited Skeletal Fragility
and What this has Taught us about Bone Structure and Function' in Cellular and
Molecular Biology of Bone (ed. Noda),

41.

Prockop, D. J.: Mutations That Alter the Primary Structure of Type I Collagen. J.
Biol. Chem. 265-26 pp. 15349-15352, 1990.

42.

Vetter, U., Weis, M. A., Mörike, M., Eanes, E. D., Eyre, D. R.: Collagen
Crosslinks and Mineral Crystallinity in Bone of Patients with Osteogenesis
Imperfecta. J. Bone Miner. Res. 8-2 pp. 133-137, 1993.

43.

Voet, D., Voet, J.G.: Biochemistry: 2nd Edition (ed. Ardwin), John Wiley and
Sons, Inc. New York, N.Y. pp 156-163, 1007-1010, 1995.

44.

Fraser, R.D.B., MacRae, T.P. Conformation in Fibrous Proteins and Related
Synthetic Polypeptides Academic Press, New York, New York, 1973.

45.

Vailas, A.C., Zernicke, R.F., Grindeland, R.E., Kaplansky, A., Durnova, G.N., Li,
K-C., Martinez, D.A. : Effects of Spaceflight on Rat Humerous Geometry,
Biomechanics, and Biochemistry. FASEB J. 4 pp 47-54, 1990.

46.

Wenstrup, R. J., Murad, S., Pinnell, S. R.: Ehlers-Danlos Syndrome Type VI:
Clinical Manifestations of Collagen Lysyl Hydroxylase Deficiency. J. Pedia.
115-3 pp. 405-409, 1989.

47.

Prockop, D. J., Kuivaniemi, H.: Inborn Errors in Collagen. Rheumatology 10
pp 246-271, 1986.

85
48.

Bailey, A. J., Wotton, S. F., Thompson, P. W.: Post-Translational Modifications
in the Collagen of Human Osteoporotic Femoral Head. Biochem. Biophys. Res.
Comm. 185-3 pp. 801-805, 1992.

49.

Amudeswari, S., Liang, J. N., Chakrabarti, B.: Polar-Apolar Characteristics and
Fibrillogenesis of Glycosylated Collagen. Collagen Rel. Res. 7 pp. 215-223,
1987.

50.

Yamauchi, M., Katz, E. P., Otsubo, K., Teraoka, K., Mechanic, G. L.: CrossLinking and Stereospecific Structure of Collagen in Mineralized and
Nonmineralized Skeletal Tissues. Connect. Tiss. Res. 21 pp. 159-169, 1989.

51.

Hodge, A.J., Petruska, J.A., 'Recent Studies with the Electron Microscope on
Ordered Aggregates of the Tropocollagen Macromolecule' in Aspects of Protein
Structure. (ed. Ramachandran) Academic Press N.Y., N.Y. 1963.

52.

Termine, J.D. : Non-Collagen Proteins in Bone. Ciba Foundation Symposium
136, pp 178-202, 1988.

53.

Eastell, R., Mallinak, N., Weiss, S., Ettinger, M., Pettinger, M., Cain, D.,
Flessland, K., Chesnut III, C.: Biological Variability of Serum and Urinary NTelopeptides of Type-I Collagen in Postmenopausal Women. J. Bone Miner. Res.
15-3 pp. 594-598, 2000.

54.

Colwell, A., Russel, G.G., Eastell, R. : Factors Affecting the Assay of Urinary 3Hydroxypyridinium Crosslinks of Collagen as Markers of Bone Resorption. Eur.
J. Clin. Invest 23 pp 341-349, 1993.

55.

Egger, C.D., Muhlbauer, R.F., Delmas, P.D., Marks, S.C., Fleisch, H. :
Evaluation of Urinary Pyridinium Crosslink Excretion as a Marker of Bone
Resorption in the Rat. J. Bone Miner. Res. 9-8 pp 1211-1219, 1994.

56.

Eyre, D.R., Koob, T.J., Van Ness, K.P. : Quantification of Hydroxypyridinium
Crosslinks in Collagen by High Performance Liquid Chromatography. Anal.
Biochem. 137 pp 380-388, 1984.

57.

Seibel, Markus J., Robins, Simon P., Bilezikian, John P.: Urinary Pyridinium
Crosslinks of Collagen, Specific Markers of Bone Resorption in Metabolic Bone
Disease. Trends Endocrinol. Metab. 3 pp 263-270, 1992.

58.

Köwitz, J., Knippel, M., Schuhr, T., Mach, J.: Alteration in the Extent of Collagen
I Hydroxylation, Isolated from Femoral Heads of Women with a Femoral Neck
Fracture Caused by Osteoporosis. Calcif. Tissue Int. 60 pp. 501-505, 1997.

86
59.

Delmas, Pierre, D., Gineyts, Evelyne., Bertholin, Annick., Garnero,
Patrick., Marchand, François.: Immunoassay of Pyridinoline Crosslink
Excretion in Normal Adult and in Pagets Disease. J. Bone Miner. Res. 8
pp 643-648, 1993.

60.

McPherson, J. M., Wallace, D. G., Sawamura, S. J., Conti, A., Condell, R. A.,
Wade, S., Piez, K.A.: Collagen Fibrillogenesis In Vitro : A Characterization of
Fibril Quality as a Function of Assembly Conditions. Collagen Rel. Res. 5 pp.
119-135, 1985.

61.

Gertz, B.J., Shao, P., Hanson, D.A., Quan, H., Harris, S.T., Genant, H.K.,
Chesnut, III, C.H., Eyre, D.R. : Monitoring Bone Resorption in Early
Postmenopausal Women by an Immunoassay for Cross-Linked Collagen Peptides
in Urine. J. Bone Miner. Res. 9-2 pp 135-142, 1994.

62.

Kamel, S., Brazier, M., Neri, V., Picard, C., Samsom, L., Desmet, G., Sebert, J.L.
Multiple Molecular Forms of Pyridinolines Cross-Links Excreted in Human Urine
Evaluated by Chromatographic and Immunoassay Methods. J. Bone Miner. Res.
10-9 pp 1385-1392, 1995.

63.

Robins, S.P., Black, D., Paterson, C. R., Reid, D. M., Duncan, A., Seibels, M. J.:
Evaluation of Urinary Hydroxypyridinium Crosslink Measurements as Resorption
Markers in Metabolic Bone Diseases. Euro. J. Clin. Invest. 21 pp 310-315, 1991.

64.

Smith, J.W. Molecular Pattern of Native Collagen. Nature 219 pp 157-158, 1968.

65.

Katz, E. P., Wachtel, E., Yamauchi, M., Mechanic, G. L.: The Structure of
Mineralized Collagen Fibrils. Conn. Tis. Res. 21 pp. 149-158, 1989.

66.

Vailas, A.C., Vanderby, R., Martinez, D.A., Ashman, R.B., Ulm, M.J.,
Grindeland, R.E., Durnova, G.N., Kaplansky, A. : Adaptations of Young Adult
Rat Cortical Bone to 14 Days of Spaceflight. J. Appl. Physiol. 73(2), Suppl.: 4S9S, 1992.

67.

Veis, A.: Phosphoproteins From Teeth and Bone. Ciba Foundation
Symposium 136, pp161-177, 1988.

68.

Vermeer, C., Jie, K-S. G., Knapen, M.H.J.: Role of Vitamin K in Bone
Metabolism. Annu. Rev. Nutr. 15 pp 1-22, 1995.

69.

Young, M. F., Ibaraki, K., Kerr, J. M., Heegaard, A.M.: 'Molecular and
Cellular Biology of the Major Non-Collagenous Proteins in Bone' in
Cellular and Molecular Biology of Bone (ed. Noda), Academic Press, Inc. San
Diego, Ca. pp 191-234, 1993.

87
70.

Hodge, A. J.: Molecular Molecules Illustrating the Possible Distributions of
'Holes' in Simple Systematically Staggered Arrays of Type-I Collagen Molecules
in Native-Type Fibrils. Conn. Tis. Res. 21 pp. 137-147, 1989.

71.

Van Den Bos, T., Beertsen, W.: Bound Phosphoproteins Enhance Mineralization
of Alkaline Phosphatase-Collagen Complexes In Vivo. J. Bone Miner. Res. 9-8
pp 1205-1209, 1994.

72.

Yeni, Y.: Fracture Mechanics of Human Cortical Bone: The Relationship of
Geometry, Microstructure and Composition with the Fracture of the Tibia,
Femoral Shaft and the Femoral Neck. 1998.

73.

Dunphy, M.J., Bhide, M. V., Smith, D. J.: Determination of Hydroxyproline in
Tissue Collagen. J. Chromotog. 420 pp. 394-397, 1987.

74.

Bidlingmeyer, B. A., Cohen, S. A., Tarvin, T. L.: Rapid Analysis of Amino Acids
Using Precolumn Derivitization. J. Chromotog. 336 pp. 93-104, 1984.

75.

Eyre, D.: New Biomarkers of Bone Resorption. J. Clin. Endo. & Metab. 74 pp.
470A-B, 1992.

76.

Bailey, A.J., Wotton, S.F., Sims, T.J., Thompson, P.W.: Biochemical Changes in
the Collagen of Human Osteoporotic Bone Matrix. Connective Tissue Research,
29 pp. 119-132, 1993.

77.

Oxlund, H., Mosekilde, Li, ∅rtoft, G.: Reduced Concentration of Collagen
Reducible Crosslinks in Human Trabecular Bone with Respect to Age and
Osteoporosis. Bone, 19-5, pp. 479-484, 1996.

78.

Bailey, A.J., Sims, T.J., Ebbesen, E.N., Mansell, J.P., Thompson, J.S., Mosekilde,
Li.: Age-Related Changes in the Biochemical Properties of Human Cancellous
Bone Collagen: Relationship to Bone Strength. Calcif. Tissue Int. 65, pp.203210, 1999.

79.

Holland, E.F. Nigel, Studd, John W.W., Mansell, Jason P., Leather, Andrew T.,
Bailey, Allen J.: Changes in Collagen Composition and Cross-links in Bone and
Skin of Osteoporotic Postmenopausal Women Treated with Percutaneous
Estradiol Implants. Obstetrics and Gynecology 83-2, pp. 180-183, 1994.

80.

Sanada, H., Shikata, J., Hamamoto, H., Ueba, Y., Yamamuro, T., Takeda, T.:
Changes in Collagen Cross-linking and Lysyl Oxidase by Estrogen. Biochim. et
Biophys. Acta 541, pp. 408-413, 1978.

81.

Ernst, M., Schmid, Ch., Froesch, E.R.: Enhanced Osteoblast Proliferation and
Collagen Gene Expression by Estradiol. Proc. Natl. Acad. Sci. 85, pp. 23072310, 1988.

88
82.

Knott, L., Bailey, A.J.: Collagen Cross-links in Mineralizing Tissues: A Review
of Their Chemistry, Function, and Clinical Relevance. Bone 22, pp. 181-187,
1998.

83.

Danielsen, C.C., Mosekilde, L., Svenstrup, B.: Cortical Bone Mass, Composition,
and Mechanical Properties in Female Rats in Relation to Age, Long-term
Ovariectomy, and Estrogen Substitution. Calcif. Tissue Int. 52, pp. 26-33, 1993.

84.

Lian, J.B., Stein, G.S., Canalis, E., Robey, P.G., Boskey, A.L.: 'Bone Formation:
Osteoblast Lineage Cell, Growth Factors, Matrix Proteins, and the Mineralization
Process' in Primer on Metabolic Bone Diseases and Disorders of Mineral
Metabolism: 4th Edition (ed. Fauvus), Am. Soc. Bone Miner. Res., Kelseyville,
CA. pp.14-29, 1999.

